Half Year Results 2026/27
19 November 2026
Halma, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for everyone, every day, today announces results for the six months to 30 September 2026.
Marc Ronchetti, Group Chief Executive, commented:
“We delivered an excellent first half, with record revenue and profit, strong growth across all three sectors, a very strong Adjusted EBIT margin2 and returns well above our cost of capital. The strength of our first half performance means we are well placed to deliver our existing guidance.
These broad-based results reinforce how our Sustainable Growth Model is delivering as designed. Strong performance today generates the capacity to invest for growth tomorrow, and in this half, we continued to invest substantially in our companies, our talent and capabilities, and in acquisitions, where investment reached a record level.
This performance is underpinned by the long-term growth drivers across our portfolio, the agility of our companies and the talent and commitment of our people. Our model is built for the longevity of growth: protecting what makes us successful and investing ahead of need. While economic and geopolitical uncertainty remains elevated, the strength of our model gives me confidence in our ability to continue compounding growth and returns for decades to come.”
Highlights
|
|
Change |
Half Year 2027 |
Half Year 2026 |
|
Revenue |
+15.8% |
£1,433.2m |
£1,237.4m |
|
Adjusted1 Earnings before Interest and Taxation (EBIT) |
+22.5% |
£345.4m |
£282.0m |
|
Adjusted EBIT margin2 |
+130bps |
24.1% |
22.8% |
|
Adjusted1 Profit before Taxation |
+21.1% |
£327.7m |
£270.5m |
|
Adjusted Earnings per Share3 |
+19.7% |
66.24p |
55.32p |
|
|
|
|
|
|
Excluding one-off4 in 2025/26: |
|
|
|
|
Revenue |
+16.7% |
£1,433.2m |
£1,228.1m |
|
Adjusted1 Earnings before Interest and Taxation (EBIT) |
+26.4% |
£345.4m |
£273.4m |
|
Adjusted1 EBIT margin2 |
+180bps |
24.1% |
22.3% |
|
|
|
|
|
|
Statutory Profit before Interest and Taxation |
+21.3% |
£307.2m |
£253.3m |
|
Statutory Profit before Taxation |
+19.5% |
£289.0m |
£241.8m |
|
Statutory Earnings per Share |
+17.8% |
58.22p |
49.44p |
|
|
|
|
|
|
Interim Dividend per Share5 |
+7% |
10.30p |
9.63p |
|
Adjusted Return on Total Invested Capital (ROTIC)6 |
+110bps |
17.3% |
16.2% |
- Record revenue:
- Strong organic7 revenue growth
- +13.1% organic7,8; includes photonics premium9 growth of c.5pp, implying a photonics organic7 growth rate of c.30%, in line with expectations
- Record Adjusted1
EBIT:
- Very strong Adjusted1 EBIT growth +26.4%8 ; +17.4% organic7,8
- Adjusted EBIT margin2 up 180bps8 to 24.1%8 (2025/26: 22.3%8)
- Broad-based growth
across all three sectors:
- Revenue growth in all sectors on an organic7 and reported basis
- Double-digit Adjusted1 profit growth in all sectors on an organic7 and reported basis
- Adjusted EBIT margin2 increased in all sectors8
- Continued high returns:
- Adjusted ROTIC6 increased 110bps to 17.3% (2025/26: 16.2%)
- Solid cash performance:
- Adjusted cash conversion10 of 85% (2025/26: 79%)
- Expect full year adjusted cash conversion10 in line with 90% KPI
- Record strategic
investment:
- R&D investment increased 8.1% to £63.9m (2025/26: £59.1m)
- Six acquisitions completed in the first half for record £516m consideration11
- Two further acquisitions completed since the half year end for c.£55m consideration11
- Actively managing the portfolio: three disposals completed in the first half
- Healthy pipeline of potential acquisitions
- Continued balance sheet
strength:
- Net debt/Adjusted1 EBITDA12 of 1.26 times (end March 2026: 1.16 times)
- Leverage higher than year end, reflecting record acquisition spend; well within our operating range of up to two times
- Interim dividend5 +7%:
- Reflects the Board’s continued confidence in the Group’s growth prospects
Outlook for the 2027 financial year
We have made a good start to the second half of the year. The strength of our first half performance means we are well placed to deliver our existing guidance for the 2027 financial year.
While our companies continue to experience varied conditions in their end markets and economic and geopolitical uncertainty remains elevated, we continue to expect to deliver, for the year as a whole, low double-digit percentage organic7 constant currency revenue growth. This guidance includes premium9 growth of approximately five percentage points from our photonics business, implying an organic7 constant currency photonics growth rate of approximately 30%. Adjusted EBIT margin2 is expected to be in the range of 23.5% to 24%.
This guidance is supported by our Group order intake, which remains ahead of both revenue in the year to date and the comparable period last year.
Notes:
- Adjusted to remove, where relevant, the amortisation and impairment of acquired intangible assets; acquisition items; significant restructuring costs; profit or (loss) on disposal of operations, and impairment of associates, totalling £38.2m (2025/26: £28.7m). See note 2 to the Condensed Interim Financial Statements for details.
- Adjusted1 EBIT margin is defined as Adjusted1 Earnings before Interest and Taxation from continuing operations expressed as a percentage of revenue from continuing operations.
- Adjusted to remove, where relevant, the amortisation and impairment of acquired intangible assets, acquisition items, significant restructuring costs; profit or (loss) on disposal of operations, impairment of associates, and the associated taxation thereon. See note 2 to the Condensed Interim Financial Statements for details.
- On 15 May 2025, Nuvonic, an Environmental & Analysis Sector company, granted FluidSmile Fluid Tech Ltd (FluidSmile), a longstanding partner in China, an exclusive trademark licence and related manufacturing and distribution rights to sell certain Nuvonic products in China and other agreed southeastern Asian markets, for RMB95m (£9.9m). Nuvonic also acquired a 35% associate interest in FluidSmile for RMB95m on the same date. As a result of these transactions, one-off revenue of £9.9m and Adjusted1 profit of £9.3m were recognised in financial year 2026, which constituted a 30bps increment to Adjusted1 EBIT margin2 (H1 25/26: 50bps).
- Interim dividend declared per share.
- Adjusted Return on Total Invested Capital (ROTIC) is defined as Adjusted1 Profit after taxation as a percentage of average Total Invested Capital. See note 9 to the Condensed Interim Financial Statements for details.
- Organic measures exclude the effect of movements in foreign exchange rates on the translation of revenue and Adjusted1 Profit into Sterling, as well as acquisitions in the year following completion and disposals. See note 9 to the Condensed Interim Financial Statements for details.
- Excluding the one-off from the Nuvonic transaction in the prior period.4
- The photonics premium is determined as the incremental contribution to Group organic7 revenue growth from the photonics business in excess of the Group’s long-term organic7 revenue growth rate of 7%. It captures the portion of Group organic7 revenue growth, expressed in percentage points, that would not have occurred had photonics grown at the Group’s long-term organic7 revenue growth rate.
- Adjusted cash conversion is defined as Adjusted1 operating cash flow as a percentage of Adjusted1 operating profit. See note 9 to the Condensed Interim Financial Statements for details.
- Maximum total consideration on a cash- and debt-free basis.
- Adjusted1 Earnings before Interest and Taxation, Adjusted1 Profit before Taxation, Adjusted3 Earnings per Share, organic7 growth rates, ROTIC and net debt are alternative performance measures used by management. See notes 2, 6 and 9 to the Condensed Interim Financial Statements for details.
- Throughout this Report, references to Adjusted profit, unless otherwise qualified, refer to Adjusted1 Profit before interest and taxation (EBIT), as management’s preferred measure of profitability.
For further information, please contact:
|
Halma plc |
+44 (0)1494 721 111 |
|
Melanie Horton, Head of Investor Relations |
+44 (0)7554 013396 |
| MHP Group Oliver Hughes/Rachel Farrington/Ollie Hoare |
+44 (0)7817 458 804/ +44 (0)7801 894 577 [email protected] |
A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com. The webcast of the results presentation will be available on the Halma website later today: www.halma.com
About Halma
Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day.
Its purpose defines the three broad market areas where it operates:
- Safety - Protecting people, assets and critical infrastructure by addressing safety risks in public, commercial and industrial environments, and supporting a safer, more sustainable future.
- Environmental & Analysis - Monitoring the environment and ensuring the quality and availability of life-critical resources, and enabling scientific research through advanced measurement, analysis and data transmission.
- Healthcare - Meeting the growing demand for healthcare as populations age and chronic conditions rise, by supporting the discovery of new cures, the prevention, diagnosis and treatment of patient conditions, and enabling the delivery of safer, more efficient healthcare.
Halma employs over 9,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.
Halma has been named one of Britain's Most Admired Companies for the past seven years.
For more information www.halma.com.
This announcement contains certain forward-looking statements which have been made by the Directors in good faith using information available up until the date they approved the announcement. Forward-looking statements should be regarded with caution as by their nature such statements involve risk and uncertainties relating to events and circumstances that may occur in the future. Actual results may differ from those expressed in such statements, depending on the outcome of these uncertain future events.